Exelixis wins EU nod for cancer combo; Merck KGaA, Pfizer pick up orphan designation;

@FierceBiotech: FierceBiotech Radio on the ins and outs of 'Pfizergan' and whatever it is Martin Shkreli's doing. More | Follow @FierceBiotech

@JohnCFierce: Any journos who would like to attend our  breakfast event on Big Data? Drop me a line @ [email protected] More info | Follow @JohnCFierce

> Exelixis ($EXEL) won European approval for the cancer treatment cobimetinib, to be used in tandem with partner Roche's ($RHHBY) Zelboraf in melanoma. The combination won FDA approval earlier this month. News

> Merck KGaA and Pfizer ($PFE) secured a European orphan drug designation for the cancer treatment avelumab, a checkpoint inhibitor in development for Merkel cell carcinoma. More

Medical Device News

@FierceMedDev: Cigna rolls out new coverage policy for whole exome sequencing. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists roll out innovative health-tracking device for guide dogs. FierceAnimalHealth story | Follow @EmilyWFierce

> Entellus wins FDA clearance for its endoscope to treat blocked sinus passages. More

> Alphabet gives startups a lesson in financial management. Article

Pharma News

@FiercePharma: Scientists roll out innovative health-tracking device for guide dogs. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI:  warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce

> Amgen nabs Kyprolis OK in Europe as U.S. competition mounts. Story

> Xellia Pharma buys former Boehringer Ben Venue plant, once the poster child of quality failings. Article

Pharma Marketing News

> Meda breaks down asthma with Medikidz comic book series for children. Report

> Kantar Media survey: Not all docs hate all ads. Article

> Turing sidesteps list-price discount on jacked-up therapy Daraprim. Item

> Purple haze: Dr. Reddy's strikes back at AstraZeneca in Nexium court battle. Story

> If TV's everywhere, then where does pharma need to be? More

Biotech Research News

> Sanford Burnham team sees promise in new melanoma drug. More

> Fruit flies may provide a biomarker for early-onset Parkinson's. Item

> U.K. investigators publish small, promising study of Victoza for NASH. Report

> Arno's HDAC inhibitor looks promising in preclinical cachexia study as cash runs low. Story

> Mount Sinai team maps a key combo role for new checkpoint drugs. Article

Vaccines News

> Daiichi Sankyo, Sanofi to launch DPT-polio vaccine in Japan. News

> Vaxart's oral RSV candidate protects in preclinical challenge. Report

> SUNY Upstate Medical University, U.S. Army start $12M partnership toward dengue vaccine. More

> FDA expands indication of Emergent BioSolutions anthrax vaccine. Article

> Celldex's brain cancer vaccine Rintega shows survival advantage at 2-year mark. Story

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.